| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
- Ecto-5'-nucleotidase (CD73): CD73-IN-1 is a selective inhibitor of CD73, with an IC₅₀ of 0.048 μM for human CD73 and 0.052 μM for mouse CD73 [1]
- Other nucleotidases (CD39, alkaline phosphatase): CD73-IN-1 shows no significant inhibition (IC₅₀ > 10 μM) [1] |
|---|---|
| ln Vitro |
1. CD73 enzyme inhibition: CD73-IN-1 dose-dependently inhibits recombinant human and mouse CD73 activity, with IC₅₀ values of 0.048 μM and 0.052 μM, respectively. At 1 μM, it inhibits human CD73 by 96% and mouse CD73 by 94% compared to vehicle control [1]
2. Inhibition of adenosine generation in cells: A549 cells (high CD73 expression) treated with CD73-IN-1 (0.1 μM) and AMP (100 μM) showed a 89% reduction in extracellular adenosine levels vs. vehicle. No significant effect on adenosine levels was observed in CD73-knockdown A549 cells [1] 3. Immune cell activation: CD73-IN-1 (0.05 μM) enhanced IFN-γ secretion by human peripheral blood mononuclear cells (PBMCs) co-cultured with A549 cells (2.8-fold increase vs. vehicle). It also increased CD8⁺ T cell proliferation (1.9-fold) and cytotoxicity against A549 cells (lysis rate: 42% vs. 18% in vehicle) [1] 4. Selectivity: CD73-IN-1 (10 μM) showed no inhibitory activity against CD39, alkaline phosphatase, or other kinases (e.g., EGFR, PI3K), confirming high selectivity for CD73 [1] |
| ln Vivo |
1. Antitumor efficacy in A549 xenograft model: Nude mice bearing A549 tumors were treated with CD73-IN-1 (10, 30 mg/kg oral gavage, once daily) for 21 days. The 30 mg/kg group showed a tumor growth inhibition rate (TGIR) of 86%, and the 10 mg/kg group showed a TGIR of 62% vs. vehicle. Tumor tissue analysis revealed reduced extracellular adenosine levels (75% reduction) and increased CD8⁺ T cell infiltration (2.5-fold) [1]
2. Inhibition of adenosine production in mice: C57BL/6 mice were administered CD73-IN-1 (30 mg/kg oral) 1 hour before intraperitoneal injection of AMP (20 mg/kg). Plasma adenosine levels were reduced by 78% compared to vehicle control [1] |
| Enzyme Assay |
1. CD73 enzyme activity inhibition assay: Recombinant human/mouse CD73 protein was incubated with serial concentrations of CD73-IN-1 (0.001–10 μM) and substrate AMP (50 μM) in reaction buffer at 37°C for 1 hour. The generated adenosine was quantified by high-performance liquid chromatography (HPLC) or a specific adenosine detection kit. IC₅₀ values were calculated from dose-response curves of enzyme activity inhibition [1]
2. Nucleotidase selectivity assay: Recombinant CD39, alkaline phosphatase, and other kinases were incubated with CD73-IN-1 (10 μM) and their respective substrates. Enzyme activity was measured via substrate consumption or product formation, and inhibition percentage was calculated relative to vehicle control [1] |
| Cell Assay |
1. Extracellular adenosine detection assay: A549 cells (wild-type and CD73-knockdown) were seeded in 24-well plates and treated with CD73-IN-1 (0.01–1 μM) for 1 hour, followed by addition of AMP (100 μM). After 4 hours of incubation, culture supernatants were collected, and adenosine levels were quantified by HPLC [1]
2. PBMC- tumor cell co-culture assay: Human PBMCs were isolated and co-cultured with A549 cells at a 10:1 ratio in the presence of CD73-IN-1 (0.01–0.5 μM) for 72 hours. IFN-γ levels in supernatants were measured by ELISA. CD8⁺ T cell proliferation was detected by flow cytometry (CFSE staining), and cytotoxicity was assessed by lactate dehydrogenase (LDH) release assay [1] |
| Animal Protocol |
1. A549 xenograft model: Female nude mice were subcutaneously inoculated with A549 cells (5×10⁶ cells/mouse). When tumors reached 100–150 mm³, mice were randomly divided into vehicle (10% DMSO/40% PEG400/50% saline) and CD73-IN-1 groups (10, 30 mg/kg). The compound was administered via oral gavage once daily for 21 days. Tumor volume and body weight were measured every 2 days. At the end of treatment, tumors were collected for adenosine quantification and CD8⁺ T cell infiltration analysis (flow cytometry) [1]
2. Plasma adenosine inhibition model: C57BL/6 mice were randomly divided into vehicle and CD73-IN-1 (30 mg/kg) groups. The compound was administered via oral gavage, and 1 hour later, all mice received AMP (20 mg/kg, intraperitoneal injection). Thirty minutes after AMP administration, blood was collected, and plasma adenosine levels were quantified by HPLC [1] 3. Acute toxicity study: SD rats were administered CD73-IN-1 via oral gavage at doses of 50, 100, 200 mg/kg. Mice were monitored for 14 days for mortality, behavioral abnormalities, and body weight changes. At the end of the study, blood was collected for biochemical analysis, and major organs were harvested for histopathological examination [1] |
| ADME/Pharmacokinetics |
1. Oral bioavailability: The oral bioavailability (F) of CD73-IN-1 in SD rats after oral administration of 30 mg/kg was 52%[1] 2. Plasma pharmacokinetics: Intravenous injection (10 mg/kg, rats) resulted in t₁/₂ = 4.6 ± 0.5 h, Cₘₐₓ = 1280 ± 130 ng/mL, and AUC₀₋∞ = 5640 ± 580 ng·h/mL. Oral administration (30 mg/kg, rats) resulted in t₁/₂ = 5.1 ± 0.6 h, Cₘₐₓ = 680 ± 75 ng/mL, AUC₀₋∞ = 5920 ± 610 ng·h/mL [1]
3. Tissue distribution: The highest concentrations of CD73-IN-1 (30 mg/kg) in rats were found in the liver (11.2 ± 1.3 μg/g), kidney (8.9 ± 0.9 μg/g), and tumor (4.5 ± 0.5 μg/g) 2 h after administration; the brain penetration was lower (0.28 ± 0.03 μg/g) [1] 4. Metabolic stability: In vitro liver microsomal incubation experiments showed that t₁/₂ = 48 ± 5 min (human liver microsomal) and 55 ± 6 minutes (rat liver microsomes) [1] |
| Toxicity/Toxicokinetics |
1. Acute toxicity: No deaths or behavioral abnormalities were observed in SD rats after oral administration of CD73-IN-1 at doses up to 200 mg/kg within 14 days. Weight change was ≤5% (compared to the control group)[1]
2. Biochemical and histopathological analysis: No significant changes were observed in liver function (ALT, AST), kidney function (BUN, creatinine), or hematological parameters (WBC, RBC, platelets) in rats orally administered 200 mg/kg CD73-IN-1. No obvious tissue damage was observed in histopathological examination of the liver, kidney, heart, lung, and spleen[1] 3. Plasma protein binding rate: The plasma protein binding rate of CD73-IN-1 in human plasma was 91±2%, and the plasma protein binding rate in rat plasma was 89±3%[1] |
| References | |
| Additional Infomation |
1. CD73-IN-1 is a 5-sulfonyl-2-hydroxybenzamide derivative designed as a selective small molecule inhibitor of CD73[1]
2. Its mechanism of action involves competitive binding to the active site of CD73, inhibiting the conversion of AMP to adenosine. The reduction in adenosine levels can alleviate adenosine-mediated immunosuppression, thereby enhancing the antitumor immune response[1] 3. The compound has shown strong antitumor activity in preclinical models, supporting its potential for the treatment of CD73-overexpressing solid tumors[1] 4. CD73-IN-1 has high selectivity for CD73, low off-target effects and good pharmacokinetic properties, making it suitable for oral administration[1] |
| Molecular Formula |
C18H17N3O4S
|
|---|---|
| Molecular Weight |
371.410282850266
|
| Exact Mass |
371.093
|
| CAS # |
2132396-40-6
|
| PubChem CID |
130406413
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
645
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(N)(=O)C1=CC(S(NC2=CC3=C(C=C2)C=C(C2CC2)N3)(=O)=O)=CC=C1O
|
| InChi Key |
YUGALILHRFUCAY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H17N3O4S/c19-18(23)14-9-13(5-6-17(14)22)26(24,25)21-12-4-3-11-7-15(10-1-2-10)20-16(11)8-12/h3-10,20-22H,1-2H2,(H2,19,23)
|
| Chemical Name |
5-[(2-cyclopropyl-1H-indol-6-yl)sulfamoyl]-2-hydroxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~150 mg/mL (~403.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6924 mL | 13.4622 mL | 26.9244 mL | |
| 5 mM | 0.5385 mL | 2.6924 mL | 5.3849 mL | |
| 10 mM | 0.2692 mL | 1.3462 mL | 2.6924 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
